NTQ5082
Phase 3Small molecule
NTQ5082 is one of 172 small molecule programs targeting Interaction. It is currently in Phase 3.
6
Indications
7
Total Trials
7
Active Trials
171
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
242 competitors in Efficacy and Safety
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Savaysa
Daiichi SankyoPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Rilutek
AAzurity Pharmaceuticals
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
UPLIZNA
HHorizon Therapeutics Ireland DAC
Phase 3
DWP16001
Daewoong Pharmaceutical Co. LTD.Phase 3
NTQ5082
NNanjing Chia-tai Tianqing Pharmaceutical
Phase 3
Becotatug Vedotin
FFudan University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Paroxysmal Nocturnal Hemoglobinuria2 trials
IgA Nephropathy1 trial
Unspecified2 trials
A Drug-Drug Interaction Study Between NTQ5082 Capsules and Midazolam Oral Solutio
Not yet recruiting·TThe Third Xiangya Hospital of Central South University·Phase 1·NCT07745439·18 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NTQ5082. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details